Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis

  title={Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis},
  author={Arpan R. Mehta and Rachel Walters and Fergal M. Waldron and Suvankar Pal and Bhuvaneish T. Selvaraj and Malcolm Robert Macleod and Giles E. Hardingham and Siddharthan Chandran and Jenna M. Gregory},
  journal={Brain Communications},
Abstract Interventions targeting mitochondrial dysfunction have the potential to extend survival in preclinical models of amyotrophic lateral sclerosis. The aim of this systematic review was to assess the efficacy of targeting mitochondria as a potential therapeutic target in amyotrophic lateral sclerosis. Preclinical studies written in the English language were identified with no restrictions on publication date from PubMed, Medline and EMBASE databases. All studies adopting interventions… 

Figures from this paper

Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis: a systematic review of in vitro studies
Cerebrospinal fluid cytotoxicity is a feature of sporadic and possibly also of familial forms of amyotrophic lateral sclerosis, and further research is, however, required to better characterize its underlying mechanisms and to establish its possible contribution to amyotroph lateral sclerosis pathophysiology.
Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis
Axonal dysfunction is a common phenotype in neurodegenerative disorders, including in amyotrophic lateral sclerosis (ALS), where the key pathological cell-type, the motor neuron (MN), has an axon
Endoplasmic reticulum-mitochondria signaling in neurons and neurodegenerative diseases.
The role of MAMs and ER-mitochondria signaling within neurons and how damage of the ER-Mitochondria axis leads to a disruption of vital processes causing eventual neurodegeneration are focused on.
Regulation of Endoplasmic Reticulum–Mitochondria Tethering and Ca2+ Fluxes by TDP-43 via GSK3β
It is demonstrated that TDP-43 down-regulation decreases MERCs density, thereby remarkably reducing mitochondria Ca2+ uptake after ER Ca2 + release and suggested that the observed cellular alterations are correlated to increased expression/activity of GSK3β, previously associated with MERCs disruption.
The second volume of Brain Communications, launched in March 2019, was an adventure for the team and a fantastic start towards their goal to develop a journal that publishes rigorous studies in translational neuroscience.
The Link between Oxidative Stress, Redox Status, Bioenergetics and Mitochondria in the Pathophysiology of ALS
Placing oxidative stress as a main pathophysiological mechanism, the molecular interactions and metabolic flows involved are analyzed and potential therapeutic approaches targeting mitochondrial biology to slow disease progression are discussed.
Defining novel functions for cerebrospinal fluid in ALS pathophysiology
It is proposed that a CSF model could potentially offer additional avenues to explore currently unexplained features of ALS, ultimately leading to new treatment options for people with ALS.


Mitochondrial dysfunction in amyotrophic lateral sclerosis.
Mitochondrial dysfunction in ALS
Miro1 deficiency in amyotrophic lateral sclerosis
It is found that excessive glutamate challenge lead to significant reduction of Miro1 expression in spinal cord motor neurons both in vitro and in mice, and this finding suggests glutamate excitotoxicity as a likely cause of Mro1 deficiency.
mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases.
SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments
The SOD1 and TDP-43 animal models created to date are summarised, report on recent findings supporting the potential mechanisms of ALS pathogenesis, and correlate this understanding with current developments in the clinic.
Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases
Details on and discuss pitfalls of existing experimental approaches to assess mitochondrial function in in vitro cellular models of neurodegenerative diseases, including specific protocols for the measurement of oxygen consumption rate in primary neuron cultures, and single-neuron, time-lapse fluorescence imaging of the mitochondrial membrane potential and mitochondrial NAD(P)H.
Modelling amyotrophic lateral sclerosis: progress and possibilities
The different model systems used to study ALS are reviewed and how they have contributed to the current understanding of the etiology and pathology of this neurodegenerative disease are discussed.
The role of mitochondria in amyotrophic lateral sclerosis
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Riluzole 100 mg daily is reasonably safe and probably prolongs survival by about two months in patients with amyotrophic lateral sclerosis.